Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model
about
Current prospects for the fluoroquinolones as first-line tuberculosis therapyAntituberculosis therapy for 2012 and beyondA medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosisRising to the challenge: new therapies for tuberculosisCurrent strategies to treat tuberculosisRapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamideEstablishment and validation of whole-cell based fluorescence assays to identify anti-mycobacterial compounds using the Acanthamoeba castellanii-Mycobacterium marinum host-pathogen systemNew anti-tuberculosis drugs and regimens: 2015 updatePipeline of drugs for related diseases: tuberculosis[Better search strategies, hopeful candidates. The search for new antimycobacterial drugs].Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosisClinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tubercuIn vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.Pharmacokinetic and pharmacodynamic evaluation of AZD5847 in a mouse model of tuberculosis.Investigational antimicrobial agents of 2013.PA-824 exhibits time-dependent activity in a murine model of tuberculosis.Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosisLinezolid for treatment of chronic extensively drug-resistant tuberculosis.The challenge of new drug discovery for tuberculosis.Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.Modeling tuberculosis in nonhuman primates.Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosisDrug-resistant tuberculosis: emerging treatment options.Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosisCurrent development and future prospects in chemotherapy of tuberculosisIn silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatmentSyntheses and biological studies of novel spiropiperazinyl oxazolidinone antibacterial agents using a spirocyclic diene derived acylnitroso Diels-Alder reaction.New drugs to treat tuberculosis.Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of TuberculosisActivity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.New drugs and regimens for treatment of TB.New antibiotic agents in the pipeline and how they can help overcome microbial resistance.World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?
P2860
Q26823843-7FD395A8-35E8-4E6F-9A51-16B719AC88CEQ26829101-37B0002A-D286-4638-9FF1-310B6DBBACBCQ27004482-047FB1E2-C978-400E-9689-C4DFC8BB6755Q27011672-05CBD255-1E25-4A38-989A-19A043876D6FQ28075252-84FD6970-1FF1-4BF8-B179-119E83807369Q28478966-142C1819-7C88-4F70-A0BA-32271A8C70C0Q28539402-2943703B-6191-4EB2-A13E-061B3961C1CEQ28596775-B01C74AB-0CBD-4F07-8838-50D432B091A4Q28818217-7EED3221-C626-4D7E-ACDE-723EEE40704DQ30318128-9CEFF5B7-FC59-4019-93A9-AA95D69AD738Q33623003-A9EF6F7D-007B-453C-AAE4-DD5573B69A74Q33760793-50AAA9A8-0F49-4DD1-A500-9AF752627355Q33798120-C95A4D3B-BEDB-477D-9DE0-B139991D65D8Q33798173-165187ED-15F0-4D89-9127-51475159A912Q33798492-19D7353C-97CA-4EB0-8331-023A22F9C5A1Q34375204-50D59CE2-220A-4AA6-856D-F7DB7C14F998Q34483632-4B6C9512-1E6E-4DD0-9164-5DD422682840Q34529109-569D9FA8-1243-4E39-959F-7726368E1D9BQ34644127-DE74A2E3-0F6A-497D-A3B7-D53008BBCDD2Q34660424-4DEE8F45-BD0E-4636-B6A3-60C9416323BCQ34737143-2E5CBDD2-F3E9-45C3-A322-D81EB036F4E2Q34737298-3BBB7AFA-854E-4F2B-B255-CC0C3370C1CEQ34922056-B25D7FD5-148E-4AF4-AC13-36DC3E19833DQ34930509-33EF6E12-5069-40E4-87AD-9DB270F85CACQ35598474-F8C6C220-EFCA-4388-AC14-ACE0E03734D6Q35683967-BC570EC8-54C1-4BA3-B5A1-50E2FA54534CQ35687128-B7C9AF66-A7C0-49BC-BF66-9CAF78747AF8Q35705874-8EEFD1C7-20E2-49E3-B575-C9D465AC8C83Q35960910-710FA1AE-9AB8-47AC-BAE7-FF47F52E4A84Q35997992-9EF0C11C-2B89-49AB-A99E-81B3B6B88B64Q36018409-AA3CBBA0-8AA0-4862-8E07-7FE4CB95689CQ36018542-5F8188F1-BF81-4C21-BBB1-70F45E70DBC5Q36094215-DB989C69-8F80-47EE-9EB0-5C2B96336F22Q36364155-BBBD620C-6630-4D68-B214-D4D93405F2CDQ36439105-85C5C684-44D5-424B-89B2-A93BEF8C51F3Q36613180-70B50188-74C2-4B9A-8385-6A864E7A0A44Q36825354-95694323-2C56-4027-96EC-BD2252F60A5CQ36845895-3B724FCC-D8A6-4619-A5C6-BE32BF44BB2AQ36957270-C588E138-9988-49DD-A074-9D66F75C52CFQ36969745-B9980434-E4E8-487B-9D53-DD4EB64243B0
P2860
Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Promising antituberculosis act ...... of linezolid in a murine model
@en
Promising antituberculosis act ...... f linezolid in a murine model.
@nl
type
label
Promising antituberculosis act ...... of linezolid in a murine model
@en
Promising antituberculosis act ...... f linezolid in a murine model.
@nl
prefLabel
Promising antituberculosis act ...... of linezolid in a murine model
@en
Promising antituberculosis act ...... f linezolid in a murine model.
@nl
P2093
P2860
P356
P1476
Promising antituberculosis act ...... of linezolid in a murine model
@en
P2093
C K Stover
E Nuermberger
J H Grosset
K N Williams
P2860
P304
P356
10.1128/AAC.01182-08
P407
P577
2008-12-15T00:00:00Z